NEW YORK, Jan. 12, 2018 /PRNewswire/ -- WallStEquities.com strives to bring the best free research to the investment community. Today we are offering reports on ACHC, MD, ANTM, and DVA which can be accessed for free by signing up to www.wallstequities.com/registration. Focus has been shifted by WallStEquities.com on the Healthcare sector, which provides goods and services to treat patients with curative, preventive, rehabilitative, and palliative care. Lined up for scanning this morning are: Acadia Healthcare Co. Inc. (NASDAQ: ACHC), MEDNAX Inc. (NYSE: MD), Anthem Inc. (NYSE: ANTM), and DaVita Inc. (NYSE: DVA). All you have to do is sign up today for this free limited time offer by clicking the link below.
www.wallstequities.com/registration
Acadia Healthcare
Franklin, Tennessee headquartered Acadia Healthcare Co. Inc.'s stock finished Thursday's session 4.18% higher at $34.38 with a total trading volume of 845,070 shares. Over the last month, the Company's shares have advanced 7.10%. The stock is trading above its 50-day moving average by 9.90%. Moreover, shares of Acadia Healthcare, which develops and operates inpatient psychiatric facilities, residential treatment centers, group homes, substance abuse facilities, and outpatient behavioral healthcare facilities to serve the behavioral health and recovery needs of communities in the US, the UK, and Puerto Rico, have a Relative Strength Index (RSI) of 66.37. Get the full research report on ACHC for free by clicking below at:
www.wallstequities.com/registration/?symbol=ACHC
MEDNAX
Shares in Sunrise, Florida headquartered MEDNAX Inc. rose 1.44%, ending yesterday's session at $54.17 with a total trading volume of 654,100 shares. The stock has gained 5.33% in the past month and 25.13% in the previous three months. The Company's shares are trading 9.13% above their 50-day moving average and 4.60% above their 200-day moving average. Moreover, shares of MEDNAX, which together with its subsidiaries, provides neonatal, anesthesia, maternal-fetal, and other pediatric subspecialties physician services in the US and Puerto Rico, have an RSI of 65.88.
On December 13th, 2017, research firm Piper Jaffray initiated an 'Overweight' rating on the Company's stock, with a target price of $58 per share.
On January 10th, 2018, MEDNAX announced its acquisition of Tri-Valley Neonatal Medical Group, Inc., a private neonatology physician practice in Van Nuys, California that provides neonatology and newborn nursery services. This was a cash transaction, and it is expected to be immediately accretive to earnings. No additional terms of the transaction were disclosed. Find your free research report MD at:
www.wallstequities.com/registration/?symbol=MD
Anthem
On Thursday, Indianapolis, Indiana headquartered Anthem Inc.'s stock gained slightly by 0.47%, to close the day at $235.00. A total volume of 1.52 million shares was traded. The Company's shares have advanced 3.97% in the last month, 23.76% in the previous three months, and 61.15% over the past year. The stock is trading 5.23% and 20.48% above its 50-day and 200-day moving averages, respectively. Additionally, shares of Anthem, which through its subsidiaries, operates as a health benefits company in the US, have an RSI of 65.04.
On December 21st, 2017, Anthem announced the completion of its acquisition of HealthSun, one of the fastest-growing integrated Medicare Advantage health plans and health care delivery networks in Florida. With the addition of the latter, Anthem's affiliated Medicare and Medicaid plans now serve more than 650,000 consumers in Florida.
On January 03rd, 2018, research firm Piper Jaffray upgraded the Company's stock rating from 'Neutral' to 'Overweight'. Sign up today for the free research report on ANTM at:
www.wallstequities.com/registration/?symbol=ANTM
DaVita
Shares in Denver, Colorado headquartered DaVita Inc. ended the day 2.51% higher at $80.03. A total volume of 2.36 million shares was traded, which was above their three months average volume of 2.27 million shares. The stock has gained 15.13% in the last month, 46.68% in the previous three months, and 26.65% over the past year. The Company's shares are trading above their 50-day and 200-day moving averages by 23.79% and 26.63%, respectively. Furthermore, shares of DaVita, which provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease, have an RSI of 88.63.
On January 04th, 2018, research firm Bank of America/ Merrill upgraded the Company's stock rating from 'Neutral' to 'Buy'.
On January 08th, 2018, The Everett Clinic, a DaVita Medical which is a division of DaVita, announced the opening of its 8,624-square-foot clinic in Bothell, Washington. Following recent openings in Woodinville and Edmonds, the Clinic's Bothell location will be located at 9924 NE 185th Street, Suite 215. It offers family medicine with same-day visits, laboratory and X-ray services, and behavioral health services. Wall St. Equities' research coverage also includes the downloadable free report on DVA at:
www.wallstequities.com/registration/?symbol=DVA
--
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
https://wallstequities.com/legal-disclaimer/
CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:Email: [email protected] Phone number: +21-32-044-483Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
Advertisement
www.wallstequities.com/registration
Acadia Healthcare
Franklin, Tennessee headquartered Acadia Healthcare Co. Inc.'s stock finished Thursday's session 4.18% higher at $34.38 with a total trading volume of 845,070 shares. Over the last month, the Company's shares have advanced 7.10%. The stock is trading above its 50-day moving average by 9.90%. Moreover, shares of Acadia Healthcare, which develops and operates inpatient psychiatric facilities, residential treatment centers, group homes, substance abuse facilities, and outpatient behavioral healthcare facilities to serve the behavioral health and recovery needs of communities in the US, the UK, and Puerto Rico, have a Relative Strength Index (RSI) of 66.37. Get the full research report on ACHC for free by clicking below at:
Advertisement
www.wallstequities.com/registration/?symbol=ACHC
MEDNAX
Shares in Sunrise, Florida headquartered MEDNAX Inc. rose 1.44%, ending yesterday's session at $54.17 with a total trading volume of 654,100 shares. The stock has gained 5.33% in the past month and 25.13% in the previous three months. The Company's shares are trading 9.13% above their 50-day moving average and 4.60% above their 200-day moving average. Moreover, shares of MEDNAX, which together with its subsidiaries, provides neonatal, anesthesia, maternal-fetal, and other pediatric subspecialties physician services in the US and Puerto Rico, have an RSI of 65.88.
On December 13th, 2017, research firm Piper Jaffray initiated an 'Overweight' rating on the Company's stock, with a target price of $58 per share.
On January 10th, 2018, MEDNAX announced its acquisition of Tri-Valley Neonatal Medical Group, Inc., a private neonatology physician practice in Van Nuys, California that provides neonatology and newborn nursery services. This was a cash transaction, and it is expected to be immediately accretive to earnings. No additional terms of the transaction were disclosed. Find your free research report MD at:
www.wallstequities.com/registration/?symbol=MD
Anthem
On Thursday, Indianapolis, Indiana headquartered Anthem Inc.'s stock gained slightly by 0.47%, to close the day at $235.00. A total volume of 1.52 million shares was traded. The Company's shares have advanced 3.97% in the last month, 23.76% in the previous three months, and 61.15% over the past year. The stock is trading 5.23% and 20.48% above its 50-day and 200-day moving averages, respectively. Additionally, shares of Anthem, which through its subsidiaries, operates as a health benefits company in the US, have an RSI of 65.04.
On December 21st, 2017, Anthem announced the completion of its acquisition of HealthSun, one of the fastest-growing integrated Medicare Advantage health plans and health care delivery networks in Florida. With the addition of the latter, Anthem's affiliated Medicare and Medicaid plans now serve more than 650,000 consumers in Florida.
On January 03rd, 2018, research firm Piper Jaffray upgraded the Company's stock rating from 'Neutral' to 'Overweight'. Sign up today for the free research report on ANTM at:
www.wallstequities.com/registration/?symbol=ANTM
DaVita
Shares in Denver, Colorado headquartered DaVita Inc. ended the day 2.51% higher at $80.03. A total volume of 2.36 million shares was traded, which was above their three months average volume of 2.27 million shares. The stock has gained 15.13% in the last month, 46.68% in the previous three months, and 26.65% over the past year. The Company's shares are trading above their 50-day and 200-day moving averages by 23.79% and 26.63%, respectively. Furthermore, shares of DaVita, which provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease, have an RSI of 88.63.
On January 04th, 2018, research firm Bank of America/ Merrill upgraded the Company's stock rating from 'Neutral' to 'Buy'.
On January 08th, 2018, The Everett Clinic, a DaVita Medical which is a division of DaVita, announced the opening of its 8,624-square-foot clinic in Bothell, Washington. Following recent openings in Woodinville and Edmonds, the Clinic's Bothell location will be located at 9924 NE 185th Street, Suite 215. It offers family medicine with same-day visits, laboratory and X-ray services, and behavioral health services. Wall St. Equities' research coverage also includes the downloadable free report on DVA at:
www.wallstequities.com/registration/?symbol=DVA
--
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
https://wallstequities.com/legal-disclaimer/
CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:Email: [email protected] Phone number: +21-32-044-483Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
View original content:http://www.prnewswire.com/news-releases/free-research-reports-on-these-healthcare-stocks----acadia-healthcare-mednax-anthem-and-davita-300581885.html
SOURCE Wall St. Equities
